> 首页 > 产品 > 一抗 > 基因重组 > Anti-MUC16 Reference Antibody (Sofituzumab vedotin)

Anti-MUC16 Reference Antibody (Sofituzumab vedotin)

Recombinant Antibody

Anti-MUC16 Reference Antibody (Sofituzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-MUC16 Reference Antibody (Sofituzumab vedotin) is 100%, determined by SEC-HPLC.
The drug-to-antibody ratio (DAR) of the Anti-MUC16 Reference Antibody (Sofituzumab vedotin) is 4.3.
Hela cells were stained with Anti-MUC16 Reference Antibody (Sofituzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50 is 0.7890 ug/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	B5ME49
Reactivity	Human
Clonality	ADC
Isotype	IgG1
Calculated MW	150 KDa

Additional Information
Target/Specificity	MUC16
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	MMAE
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.